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http://dx.doi.org/10.1016/j.immuni.2012.05.018Over the last 5 years a compendium of
structural and functional data on the reac-
tionsof T cell receptors (TCRs) that include
the germline element Vb8.2 and other TCR
Vbs with related sequences have revealed
a very similar interaction motif between
residues on the tips of TCR CDR1b,
CDR2b, and the a1 helix of the MHC
(Figure S1A available online; exemplified
in Dai et al., 2008; Feng et al., 2007; Rein-
herz et al., 1999). The motif includes a trio
of amino acids composed of residues
Tyr48, Tyr50, and Glu56 (called Tyr46,
Tyr48, and Glu54 in papers by some of
us) in the CDR2bs of Vbs that are related
to Vb8.2. This has led to the proposal
that this conserved motif represents an
evolutionary signature of germline speci-
ficity. Functionally, mutation of any of
these three amino acids in CDR2b usually
results in impaired binding to the MHC by
TCRs in which the mutant Vbs are
included. This is so even in experiments
in which the TCRa chain was allowed to
adopt any possible naturally generated
sequence (Scott-Browne et al., 2009).
In a recent paper published in Immunity,
Stadinski et al. (2011) isolated TCRs that
recognized MHC class II ligands only or
cross-reacted with classical and nonclas-
sical MHC class I ligands. These TCRs
used the same Vb8.2 TCR chain (Yae62)
paired with different Va domains and
were crystallized in complex with the
same class II MHC ligand (Dai et al., 2008;
Stadinski et al., 2011). The authors suggest
that, byvirtueofpairing toanalternativeVa,
theTCRb loopconformationschangedand
the interaction site of the Vb domain was
significantly modified, leading to an
‘‘altered pMHCbindingmode’’ and ‘‘modi-fied TCRb binding reaction with MHC.’’
Theygoon toconclude that, consequently,
germline specificity, defined as conserved
pairwise interactions between Vb and
MHC amino acids, is not consistently
observed. Indeed, prior examination of
the variouscomplexesbetweenTCRscon-
taining Vb8.2 and MHC revealed that
althoughY50 of Vb8.2 (for example) almost
always interacts with MHC, it does not do
so in each case with the same atom-to-
atomcontacts (Garcia et al., 2009;Marrack
et al., 2008). As such, the idea that TCR
chains, in the course of evolution, have
evolved germline residues to interact in
a consistent way with MHC molecules
appears to have less validity. This idea is
further emphasized in the accompanying
preview by Turner and Rossjohn (2011)
who argue that because the differential
usage of Vas ‘‘enables the same Vb chain
to recognize a different region of the same
MHC,’’ the previous notions of germline
specificity based on studies of Vb8.2 are
‘‘inaccurate.’’
A close examination of the two featured
structures and the mutational data in Sta-
dinski et al. (2011) does not lead to all the
conclusions drawn. Rather, it provides
further evidence for germline specificity.
The Vb footprints of the new structures
are very similar to all previous Vb8.2-I-A
complexes. Any of the observed small
deviations fall within the range already
seen among the previous structures
(Figure S1A). Analysis of the degree of
overlap between the CDR1b and CDR2b
of the two TCRs highlighted in Stadinski
et al. (2011) reveals a root mean square
deviation (rmsd) for carbon-a atoms of
0.99 A˚ and 2.0 A˚, respectively. By compar-Immunityison, the rmsd between CDR1b and
CDR2b of either Yae62 or J809.B5 and
any of the other Vb8.2-I-A complexes
determined so far (and shown in Figure S1)
averages approximately 1.15 A˚ and 2.3 A˚
rmsd, respectively. Thus, Vb germline
contacts of Yae62 and J809.B5 in fact
deviate slightly less from one another
than from other previously determined
Vb8.2 complexes. Moreover, a closer
view of the regions of interest, the CDR1b
and CDR2b loop contacts with the a1
helix, shows a very close structural super-
imposition of not only the main chains
but also the side chains mediating the
interactions between the structures
(Figure S1B).
Certainly there are differences between
the Yae62 and J809.B5 structures. For
instance, there is an alternative rotamer
conformation of MHC residue Gln61
(Figure S1B). Also, there are some small
differences in the atom-to-atom engage-
ment ofMHCby the trio of VbCDR2amino
acids in the Stadinski et al. (2011) struc-
tures and those previously described.
However, on the whole, the involvement
of the Vb amino acid trio (Y48, Y50, and
E56) in engagement of MHCII is very
similar in all TCR-MHC II complexes that
have been studied to date.
Perhapsour hypothesis about thenature
of germline interactions between TCR V
regions and MHC has not been stated
clearly enough. We did not intend to
suggest thatanabsolutely superimposable
atomic identity, with invariant atom-to-
atom contacts, would occur in all
complexes containing this germline
element. Rather, we suggested that the
general features of the recognition motif36, June 29, 2012 ª2012 Elsevier Inc. 887
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Letterson the TCRs, principally the location of the
contact site and the centrality of the Tyr50
residue (in Vbs that include it) would be
preserved (Marrack et al., 2008). Further,
our assertion of ‘‘pairwise’’ similarity
(Feng et al., 2007) includes the idea that
germline specificity ‘‘takes two to tango.’’
Thus there must be sites on MHC proteins
that are tailored to partner with the MHC-
binding motifs on TCRs. We suggest that
these general features must have been
evolutionarily selected to allow for some
flexibility, wobble, or even shifting. This
flexibility could encompass different ro-
tamer positions of amino acids within the
recognition motif (such as the Vb-MHC
Gln61 changes noted by Stadinski et al.
[2011]) that could result in slightly different
pairings of specific amino acids. In fact,
we venture that this ability of particular
TCRamino acids tobind theirMHC ligands
in a flexible way is essential to the function
of the TCR (Marrack et al., 2008). It allows
TCRs to have some consistent specificity
for MHC while enabling their allotted
binding sites to accommodate the
demands imposed by differences in length
and amino acid composition of TCR CDR3
regions and MHC-engaged peptides.
The results of Stadinski et al. (2011) and
others (Dai et al., 2008; Feng et al., 2007;
Reinherz et al., 1999) support this idea, as
does a paper in the same issue of
Immunity that describes a strikingly super-
imposable Va3-H-2Ld germline interac-
tion motif that is preserved by TCRs
bearing different Vb chains and CDR3
sequences, as well as recognizing entirely
distinct peptide antigens through
different chemistries (Adams et al.,888 Immunity 36, June 29, 2012 ª2012 Elsev2011). In fact, in several of the aforemen-
tioned Vb8.2-I-A complexes that contain
multiple complexes in the asymmetric
unit of the crystal lattice (Reinherz et al.,
1999), slight variations in the H-bonding
networks of the interaction motif can be
seen in the different complexes, indi-
cating once again that there is malleability
to the interaction site between TCR and
MHC.
Another misunderstood issue involves
the idea that multiple modes of germ-
line-encoded interactions probably exist.
Thus, a given V region may be able to
engage different MHC targets in different
ways, but using the same V region amino
acids (Garcia et al., 2009). This notion is
most dramatically illustrated by the inter-
action of Vb8.2-bearing TCRs with the
nonclassical MHC protein CD1d. CD1d
presents antigens to TCRs that are
entirely different from those manifested
by classical MHC proteins. Moreover,
TCRs bind CD1d in a configuration that
is significantly different from that of their
engagement of conventional MHC.
Nevertheless the Vb8.2 Tyr50 residue
remains key to this interaction (Borg
et al., 2007).
Although deviations from (or excep-
tions to) the codon ‘‘rules’’ can (and will)
always be found, such as appears to be
the case for super-bulged peptide
complexes where the TCR engages the
peptide while being held away at some
distance from the MHC—much in the
manner of an antibody-peptide interac-
tion (Burrows et al., 2010)—we surmise
that for the vast majority of TCRs, MHC
specificity is germline encoded.ier Inc.SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure and
can be found with this article online at http://dx.
doi.org/10.1016/j.immuni.2012.05.018.
REFERENCES
Adams, J.J., Narayanan, S., Liu, B., Birnbaum,
M.E., Kruse, A.C., Bowerman, N.A., Chen, W.,
Levin, A.M., Connolly, J.M., Zhu, C., et al. (2011).
Immunity 35, 681–693.
Borg, N.A., Wun, K.S., Kjer-Nielsen, L., Wilce,
M.C., Pellicci, D.G., Koh, R., Besra, G.S., Bharad-
waj, M., Godfrey, D.I., McCluskey, J., and Ross-
john, J. (2007). Nature 448, 44–49.
Burrows, S.R., Chen, Z., Archbold, J.K., Tynan,
F.E., Beddoe, T., Kjer-Nielsen, L., Miles, J.J.,
Khanna, R., Moss, D.J., Liu, Y.C., et al. (2010).
Proc. Natl. Acad. Sci. USA 107, 10608–10613.
Dai, S., Huseby, E.S., Rubtsova, K., Scott-
Browne, J., Crawford, F., Macdonald, W.A., Mar-
rack, P., and Kappler, J.W. (2008). Immunity 28,
324–334.
Feng, D., Bond, C.J., Ely, L.K., Maynard, J., and
Garcia, K.C. (2007). Nat. Immunol. 8, 975–983.
Garcia, K.C., Adams, J.J., Feng, D., and Ely, L.K.
(2009). Nat. Immunol. 10, 143–147.
Marrack, P., Scott-Browne, J.P., Dai, S., Gapin, L.,
and Kappler, J.W. (2008). Annu. Rev. Immunol. 26,
171–203.
Reinherz, E.L., Tan, K., Tang, L., Kern, P., Liu, J.,
Xiong, Y., Hussey, R.E., Smolyar, A., Hare, B.,
Zhang, R., et al. (1999). Science 286, 1913–
1921.
Scott-Browne, J.P., White, J., Kappler, J.W.,
Gapin, L., and Marrack, P. (2009). Nature 458,
1043–1046.
Stadinski, B.D., Trenh, P., Smith, R.L., Bautista, B.,
Huseby, P.G., Li, G., Stern, L.J., and Huseby, E.S.
(2011). Immunity 35, 694–704.
Turner, S.J., and Rossjohn, J. (2011). Immunity 35,
660–662.
